Gilead Sciences

Vertex Pharmaceuticals

Amgen

Regeneron Pharmaceuticals

IQVIA Hlds

Alnylam Pharmaceuticals

Mettler-Toledo

Biogen

Illumina

Waters

iShares Nasdaq Biotechnology ETF

IBB tracks the performance of a modified market-cap-weighted index of US biotechnology companies listed on US exchanges.

SPDR S&P Biotech ETF

The biotech sector recently experienced a sharp reversal following a failed breakout attempt post-election. While most areas of the market surged to new heights after Donald Trump's election win on November 5, biotech ETFs like the iShares Biotechnology ETF NASDAQ: IBB and the SPDR Biotech ETF NYSE: XBI stopped short of new 52-week highs.

Is Biotech's Bull Run Over? Examining Election Impacts

iShares Russell 2000 ETF

iShares Transportation Average ETF

SPDR S&P Regional Banking ETF

VanEck Vectors Semiconductor ETF

SPDR S&P Retail ETF

The week right after the election, the stock market and investors were downright jubilant.  This past week, the best word to describe them as is disappointed (for many outside of bitcoin investors).

Key Stock Market ETFs Fall Back To Earth; What's Next?

I have commented but not focused too much on the Biotechnology Sector ETF (IBB). My weekend comments were, “IBB remains stuck in its weekly trading range.

Biotechnology Stocks Eyeing Seasonality Move Higher

I reiterate a hold rating on IBB due to its stretched valuation at nearly 20x earnings and mixed technical situation. Despite a 7% YTD gain, IBB has underperformed the S&P 500, which is up 21%, and shows negative alpha. Key support and resistance levels to watch are $138-$141 and $150, respectively, with a potential bullish move to $160.

IBB: A Near-20x P/E Is Historically Pricey, Technical Trends Neutral

Making its debut on 02/05/2001, smart beta exchange traded fund iShares Biotechnology ETF (IBB) provides investors broad exposure to the Health Care ETFs category of the market.

Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?

If you're interested in broad exposure to the Healthcare - Biotech segment of the equity market, look no further than the iShares Biotechnology ETF (IBB), a passively managed exchange traded fund launched on 02/05/2001.

Should You Invest in the iShares Biotechnology ETF (IBB)?

As a new regime and phase begin for the market and economy, after the FED cut interest rates by a surprising 50bps last Wednesday, several new opportunities and sector bull and bear markets might begin.

Biotech Boom Ahead? Key Stocks and ETFs to Watch Now

After a prolonged consolidation and downtrend following the pandemic-driven surge, the biotechnology sector is readying for a potential breakout and shifting its narrative. Represented by the iShares Biotechnology ETF NASDAQ: IBB, the sector has turned a significant corner, with previous resistance levels becoming support, setting the stage for a potential momentum shift.

Biotech Breakout: Stocks for Your Watchlist

Thanks to the prospect of lower interest rates, shares of biotech companies have doubled the gains of the broad market over the past few months.

Biotech Stocks Are Showing Signs of Life. Why the Rally Could Continue.

iShares Russell 1000 Growth ETF

Invesco QQQ

Exchange-traded funds aren't just for risk-averse investors. Many funds can give exposure to some great growth stocks.

3 ETFs for Growth Investors to Buy and Hold for Decades

Here we are, another week and another notch on the bull market belt. Last weekend, we were very bullish coming into this past week on Small Caps, Biotechnology and Regional Banks.

Key Stock Market ETFs Hanging Tough Amidst Volatility

Biotechnology companies experienced an optimistic bullish cycle in 2020-2021, leading to outperformance of the Biotech index. But the cycle of interest rate increases taking place since 2022 has caused several Biotech companies to observe cash flow issues. Advances in AI, machine learning, and generative AI are likely to accelerate drug discovery processes and optimize operations in the biotech and pharma sectors, leading to growth opportunities.

iShares Biotechnology ETF: Significant Upside Potential As Sector Gains Momentum

The biotech sector has significantly lagged behind the overall market and its leading sector, technology, year-to-date. However, following the release of the CPI data on Thursday, the biotech sector, represented by the iShares Biotechnology ETF NASDAQ: IBB, experienced a significant breakout above a multi-year resistance level.

CPI Data Sparks Rally in Biotech Stocks

On June 24, 2024 I wrote a daily called, Biotechnology Sector IBB Breakout Comes To Life: “IBB sits just below the 200-WMA. Plus, he is in the middle of the weekly channel range.

The Biotechnology Sector ETF (IBB) Clears Price Resistance

Biotech indexes lagged broader market indexes in the first half of 2024, and trade at the same level as in early 2022. Biotech valuations are closely tied to the Fed's interest rate policy and are highly correlated to the 10-year yield. Inflation is likely to trend lower, and, along with rising unemployment, should persuade the Fed to cut rates this year in September.

Biotech Stocks 2024 Second Half Outlook - Buy Biotechs

The biotechnology sector, represented by the iShares Biotechnology ETF NASDAQ: IBB, has experienced a year of consolidation. With the ETF up just 0.8%, it has underperformed the broader market, making it one of the worst-performing sectors year-to-date.

Biotech Stock Breakout: IBB Eyes Resistance with Amgen and Vertex

Over the weekend as we looked at the entire Economic Modern Family of stock market ETFs, we focused on Big Brother Biotechnology IBB as particularly intriguing. We wrote: “IBB sits just below the 200-WMA.

$IBB Biotechnology Sector ETF Breakout Comes To Life

Innovation has been a hallmark of biotechnology for decades and, despite some of the hardest sledding in many years, 2024 could be a bounce-back year for biotech stocks. The sector has suffered in this cycle.

Why the Rest of 2024 Could Be Good for Investing in Biotech Stocks

Tema Obesity & Cardiometabolic ETF

Health Care Select Sector SPDR Fund

Weight loss has long been a challenge for many people, me included. Indeed, there are an estimated 1 billion individuals living with obesity, and the Obesity World Atlas estimates this could rise to 1.9 billion by 2035.

Fighting Obesity Using ETFs

Biotech indexes, represented by IBB and XBI, have been facing pressure since March and trading at valuations seen in April 2020. The key factor influencing biotech valuations, discussed below, is expected to become more favorable in the second half as rate-cut uncertainty diminishes. While biotechs have significantly lagged behind the broader market, there is reason to be optimistic once inflation-related volatility subsides. IBB and XBI present good vehicles for biotech exposure.

For Biotech Stocks To Move Higher, This Must Move Lower

Moderna

The biotech sector and its popular ETF, the iShares Biotechnology ETF NASDAQ: IBB, have lagged the overall market during the year, with its shares slightly red. However, in recent weeks, the sector has enjoyed a significant rally after bouncing off its uptrend support and now consolidating near several major Simple Moving Averages (SMA).

Will the Biotech Sector Shift From Lagger to Leader?

iShares U.S. Aerospace & Defense ETF

Invesco Solar ETF

Global X Autonomous & Electric Vehicles ETF

Global X Internet of Things ETF

Wall Street was in great shape on Monday, with the S&P 500 experiencing its largest three-day rally of the year.

S&P 500's Best 3-Day Run in 2024: ETF Areas That Won

Ascendis Pharma

Cytokinetics

DexCom

Edwards Lifesciences

iShares U.S. Pharmaceuticals ETF

Eli Lilly

Medtronic

Novo Nordisk

SPDR S&P 500 ETF Trust

Viking Therapeutics

A new exchange-traded fund needs an edge to attract investors. This might be its industry focus — a tall order in a crowded market with ETFs covering just about any industry you can imagine.

This weight-loss ETF has performed well in its first five months. How does it compare with cheaper alternatives?

Watching certain instruments for clues on next moves, probably the best (equities) to watch is the Economic Modern Family of stock market ETFs. These ETFs cover everything from tech to regional bank stocks to small cap stocks to retail stocks and more.

What's Next For Rangebound Stock Market ETFs?

The popular iShares Biotechnology ETF NASDAQ: IBB has formed a bullish consolidation in the upper portion of its 52-week range, hinting at a significant sector-wide breakout.

News for iShares Nasdaq Biotechnology ETF ETF (IBB)